—
Supported by leading technologies along with experienced senior scientists majored in cancer therapy, Creative Biolabs specializes in combinatorial therapy services of oncolytic viruses and cancer immunotherapies on the basis of self-developed cancer therapy platforms.Immunotherapy has achieved remarkable clinical results in the last few years while oncolytic virus (OV), a replication virus which selectively invades cancer cells, have long been acknowledged to be effective in anti-cancer approaches. Recent research showed that OVs can function as an adjuvant to other immunotherapies, including cancer vaccines, cytokines, immune checkpoint inhibitors, etc. With a lot of past experience in oncolytic viruses as well as our highly qualified OncoVirapy™, Creative Biolabs has equipped itself with rich experience on oncolytic virotherapy development for combination therapy with cancer immunotherapy as mentioned above.
· Combination with Adoptive T Cell Therapy (ACT)
OVs can regulate the immune system as well as the local tumor microenvironment, thus to augment the effect of ACT. Creative Biolabs owns a well-performed immunotherapy platform to deliver services of combining oncolytic virotherapy with ATC transfer therapy, including tumor-infiltrating lymphocyte therapy (TIL) , cytokine-induced killer cell immunotherapy (DC-CIK), T-cell receptor-engineered T cells therapy(TCR-T), chimeric antigen receptor T-cell therapy (CAR-T), and dendritic cell therapy. A considerable variety of animal models with severe immune system function defects are also provided.
· Combination with Immune Checkpoint Inhibitors (ICIs)
The combination therapies of ICIs and OVs are attractive since OVs help to increase T cell recruitment and activate immune cells. Experts of Creative Biolabs have developed a wide range of ICIs and built several combination therapy platforms which are potentially suitable to achieve successful combination. Combination of OVs and ICIs services are offered, including assay development for OVs combined with ICIs, arming oncolytic virus with ICIs Payload, etc.
· Combination with Cytokines
Encoded by small genes and easy to build in oncolytic viral genomes, the cooperation of cytokines and OVs greatly intensifies responsiveness of treatment. Creative Biolabs is well-versed in combination therapy of oncolytic virus armed with cytokines. Combination of oncolytic virotherapy and cytokines services are provided including colony-stimulating factors (CSFs), interferons (IFNs), interleukin (IL), chemokines, etc. Owning one of the world’s most comprehensive cytokines products and research techniques, Creative Biolabs will offer the most suitable scheme according to clients’ research demand.
· Other Combination Therapies
Creative Biolabs has also developed scientific and efficient combination therapy platforms which contain various oncolytic virus, a wind range of chemotherapy drugs, varied OV vaccines and method of radiation therapy to fit types of disease, including tumor-associated antigen (TAA)-encoding OVs, heterologous virus prime-boost for cancer vaccination, OVs combined with radiation therapy and chemotherapy drugs combined with OVs, etc.
Aforementioned services can all be found at Creative Biolabs, and more customized services concerned with oncolytic viruses are also provided. More detailed information can be found at https://www.creative-biolabs.com/oncolytic-virus
About Creative Biolabs
Creative Biolabs is one of the recognized leaders in the field of oncolytic virotherapy development for combinatorial therapy with cancer immunotherapy. Supported by experienced scientists who have developed a complete set of in vitro and in vivo assays, the products cover adenovirus, vesicular stomatitis virus and OVs with specific modifications such as cytokine-armed OV, capsid-modified OV, reporter-encoding OV, etc. Creative Biolabs promises to provide efficient, normative and all-inclusive oncolytic virus therapy development services for clients worldwide.
Contact Info:
Name: Candy Swift
Email: Send Email
Organization: Creative Biolabs
Website: https://www.creative-biolabs.com/oncolytic-virus
Release ID: 88928372
Google
RSS